Tehran University of Medical Sciences

Science Communicator Platform

Faculty Members have conducted research related to the Regorafenib Versus Cetuximab Plus Irinotecan in Third-Line Metastatic Colorectal Cancer in Iran: A Model-Based Cost-Utility Analysis
Meysam Seyedifar
Meysam Seyedifar

Assistant Professor of Pharmacoeconomics and Pharmaceutical Administration

Pharmaceutical Management & Economics Research Center

Tehran University of Medical Sciences

All Documents
1. Cost-Utility Analysis of Erenumab Compared to Topiramate for Preventive Therapy of Migraine in Iran, Iranian Journal of Pharmaceutical Research (2024)
2. Cost-Utility Analysis of Trastuzumab-Emtansine Versus Trastuzumab for the Treatment of Residual Invasive Her-2-Positive Breast Cancer in Iran, Iranian Journal of Pharmaceutical Research (2024)
3. Regorafenib Versus Cetuximab Plus Irinotecan in Third-Line Metastatic Colorectal Cancer in Iran: A Model-Based Cost-Utility Analysis, Middle East Journal of Cancer (2024)
4. Budget Impact Analysis of Temocillin Insurance Coverage for Urinary Tract Infections Caused by Esbl-Producing Pathogens in Iran, Medicine (United States) (2023)
5. Consumers’ Willingness to Pay for Pharmacist Counselling Services and the Factors Affecting It in Community Pharmacies, Iranian Journal of Pharmaceutical Research (2023)
6. Utilization Patterns of Cardiovascular Medications in Patients With Diabetes Mellitus; a Retrospective Cross-Sectional Study, 2013-17, DARU# Journal of Pharmaceutical Sciences (2023)
7. A Comparison Between On-Demand Usage of Rfviia Vs Prophylaxis Use of Emicizumab in High Titer Inhibitory Hemophilia a Patients in Iran: A Cost-Utility Analysis, Medicine (United States) (2021)
8. Cost-Utility and Budget Impact Analysis of Adding-On Apremilast to Biologic Therapy in the Treatment of Moderate to Severe Plaque Psoriasis, an Iranian Payer Perspective, Research in Pharmaceutical Sciences (2021)
9. Economic Evaluation for Benign Prostatic Hyperplasia in Iran: Surgical Treatment or Dutasteride, Iranian Journal of Pharmaceutical Research (2021)
10. Cost-Utility of New Film-Coated Tablet Formulation of Deferasirox Vs Deferoxamine Among Major Beta-Thalassemia Patients in Iran, Medicine (United States) (2020)
11. Health-Related Quality of Life and Health Utility Values in Beta Thalassemia Major Patients Receiving Different Types of Iron Chelators in Iran, International Journal of Hematology-Oncology and Stem Cell Research (2016)